RxDoctor Payments Data

Patricia Roberts, DO

Family Medicine · Fort Worth, TXNPI 1053382846

Payments from drug & device makers

$745in general payments, 2019–2025

Across 22 payments — averaging $33.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$129
  • Avanir Pharmaceuticals, Inc.$128
  • AstraZeneca$122
  • Sunovion Pharmaceuticals Inc.$57
  • Gilead$48
  • Globus Medical$45
  • plus $215 from 9 others

What the payments were for

  • Food & beverage$745100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$745 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$68,137
Medicare patients
212
Services billed
1,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$52,265
Austedo XrDeutetrabenazine13$31,576
JardianceEmpagliflozin32$27,400
JanuviaSitagliptin Phosphate15$20,805
MounjaroTirzepatide13$16,037
Spiriva RespimatTiotropium Bromide19$15,192
EliquisApixaban19$14,327
Spiriva HandihalerTiotropium Bromide15$13,552
BaqsimiGlucagon22$11,851
JanumetSitagliptin Phos/Metformin Hcl13$11,274
LinzessLinaclotide11$9,459
Breo ElliptaFluticasone/Vilanterol22$8,653
Incruse ElliptaUmeclidinium Bromide21$7,656
Ventolin HfaAlbuterol Sulfate113$7,649
Combivent RespimatIpratropium/Albuterol Sulfate11$5,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$52,26548 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$26$31,57613 claims
Lilly USA, LLCMounjaro, Baqsimi$35$27,88835 claims
AbbVieLinzess$129$9,45911 claims
AstraZenecaSymbicort$122$4,92722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →